Age Related Macular Degeneration News and Research

RSS
Minocycline fails to slow vision loss in people with dry age-related macular degeneration

Minocycline fails to slow vision loss in people with dry age-related macular degeneration

Breakthrough $20 million OCT project aims to revolutionize eye health screening

Breakthrough $20 million OCT project aims to revolutionize eye health screening

New treatment targeting aging cells could offer lasting relief for diabetic macular edema

New treatment targeting aging cells could offer lasting relief for diabetic macular edema

MACUSTAR extends Europe-wide clinical study on intermediate age-related macular degeneration

MACUSTAR extends Europe-wide clinical study on intermediate age-related macular degeneration

Study sheds light on 7-DHC's potential to induce cell death-resistant state in tumors

Study sheds light on 7-DHC's potential to induce cell death-resistant state in tumors

Night-time artificial light exposure linked to increased risk of age-related macular degeneration

Night-time artificial light exposure linked to increased risk of age-related macular degeneration

AI Integration in the Fight Against Age-Related Macular Degeneration

AI Integration in the Fight Against Age-Related Macular Degeneration

Targeted ocular spectroscopy shines new light on retinal health

Targeted ocular spectroscopy shines new light on retinal health

Researchers develop state-of-the-art UV protective contact lenses

Researchers develop state-of-the-art UV protective contact lenses

New compound could offer an alternative to injections for people suffering from eye condition

New compound could offer an alternative to injections for people suffering from eye condition

Researchers discover new mechanism in the progression of age-related macular degeneration

Researchers discover new mechanism in the progression of age-related macular degeneration

Stem cell patch for treating macular degeneration to enter phase 2b clinical trial

Stem cell patch for treating macular degeneration to enter phase 2b clinical trial

New technology could revolutionize treatment for age-related macular degeneration

New technology could revolutionize treatment for age-related macular degeneration

MCW professor awarded $13 million NIH grant to study misplaced calcification in AMD and Alzheimer's

MCW professor awarded $13 million NIH grant to study misplaced calcification in AMD and Alzheimer's

Cell therapy using genome-edited iPS cells could be a new treatment for Fabry disease

Cell therapy using genome-edited iPS cells could be a new treatment for Fabry disease

Research finds link between biomarkers in vitreous humor of the eye and Alzheimer's disease

Research finds link between biomarkers in vitreous humor of the eye and Alzheimer's disease

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

How innovative technology aids in the fight against diabetes epidemic

How innovative technology aids in the fight against diabetes epidemic

Groundbreaking study maps molecular architecture of the visual system's integral components

Groundbreaking study maps molecular architecture of the visual system's integral components

Technology advance could enable the use of ophthalmologic OCT systems at home

Technology advance could enable the use of ophthalmologic OCT systems at home

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.